-$0.54 Earnings Per Share Expected for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) This Quarter

Brokerages expect that Aerie Pharmaceuticals, Inc. (NASDAQ:AERIGet Rating) will post earnings per share of ($0.54) for the current quarter, according to Zacks. Five analysts have made estimates for Aerie Pharmaceuticals’ earnings, with estimates ranging from ($0.61) to ($0.44). Aerie Pharmaceuticals posted earnings of ($0.67) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 19.4%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.33) to ($1.92). For the next fiscal year, analysts expect that the company will post earnings of ($1.35) per share, with EPS estimates ranging from ($1.58) to ($1.19). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERIGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.01). During the same period last year, the company posted ($0.72) earnings per share.

Several equities research analysts recently issued reports on the company. Needham & Company LLC decreased their price target on Aerie Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a report on Friday, February 25th. StockNews.com started coverage on Aerie Pharmaceuticals in a report on Thursday, March 31st. They set a “hold” rating for the company. Cowen reduced their price objective on Aerie Pharmaceuticals from $30.00 to $25.00 in a research note on Friday, February 25th. Finally, Citigroup reduced their price objective on Aerie Pharmaceuticals from $23.00 to $13.00 in a research note on Monday, February 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Aerie Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $19.52.

Several hedge funds and other institutional investors have recently modified their holdings of the company. William Blair Investment Management LLC lifted its position in shares of Aerie Pharmaceuticals by 31.6% during the 3rd quarter. William Blair Investment Management LLC now owns 2,877,149 shares of the company’s stock valued at $32,799,000 after buying an additional 690,649 shares during the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Aerie Pharmaceuticals by 39.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,678,609 shares of the company’s stock valued at $15,275,000 after buying an additional 475,017 shares during the last quarter. Levin Capital Strategies L.P. lifted its position in shares of Aerie Pharmaceuticals by 75.7% during the 1st quarter. Levin Capital Strategies L.P. now owns 1,435,876 shares of the company’s stock valued at $13,066,000 after buying an additional 618,499 shares during the last quarter. Granahan Investment Management Inc. MA lifted its position in shares of Aerie Pharmaceuticals by 0.5% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 1,394,270 shares of the company’s stock valued at $15,895,000 after buying an additional 6,299 shares during the last quarter. Finally, Schroder Investment Management Group lifted its position in shares of Aerie Pharmaceuticals by 1.5% during the 4th quarter. Schroder Investment Management Group now owns 1,352,954 shares of the company’s stock valued at $9,498,000 after buying an additional 19,990 shares during the last quarter.

Aerie Pharmaceuticals stock traded up $0.36 during trading on Friday, hitting $6.81. 512,084 shares of the company were exchanged, compared to its average volume of 520,899. The business’s 50 day moving average is $8.20 and its 200 day moving average is $8.40. Aerie Pharmaceuticals has a 52 week low of $5.46 and a 52 week high of $19.26. The company has a market capitalization of $331.10 million, a P/E ratio of -4.54 and a beta of 0.74.

About Aerie Pharmaceuticals (Get Rating)

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.

Further Reading

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.